Follicum AB (“Follicum” or “the Company”) today announces that CEO Jan Alenfall will give a presentation of the development of FOL-005 at the conference European Hair Research Society, which takes place in Bologna, Italy, 18-20 May 2018.
The presentation will be included in the part of the conference that will discuss cell-based, growth-factor-based and pharmaceutical treatments. Follicum will also present a poster with the title “FOL-005 – a novel peptide drug regulates hair growth in a Phase I/IIa study” at the same conference.
Information about the poster and the scientific program:
The presentation will take place on 19 May at 14.45
Title of the presentation: FOL-005 – Novel peptide-based hair therapeutic
Link to the scientific program: click here
Poster title: FOL-005 – a novel peptide drug regulates hair growth in a Phase I/IIa study
Poster number: 30.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com